It has been estimated that only 50% to 60% of patients respond to their initial antidepressant, and less than a third of patients achieve full remission. Therefore, clinicians have to frequently switch patients between different antidepressants for efficacy and tolerability reasons. There is a lack of data to guide clinicians on the best method of switching from one antidepressant to another. This slide set enumerates the switch over study of vilazodone, the latest and novel addition to the armamentarium of antidepressants belonging to SPARI (Serotonin Partial Agonist & Reuptake Inhibitor. The study elaborates that switching MDD patients who were non-responders to previous antidepressants (SSRIs & SNRIs) to vilazodone lead to improvement in symptoms with no significant tolerability issues.